BlackRock Investment Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

BlackRock Investment Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-9	Closed	-$6K	–	4153
2016 Q1	$6K	Hold	9	–	–	﹤0.01%	3784
2015 Q4	$8K	Buy	9 +1	+13%	+$1.32K	﹤0.01%	3763
2015 Q3	$8K	Hold	8	–	–	﹤0.01%	3793
2015 Q2	$16K	Buy	8 +5	+167%	+$7.11K	﹤0.01%	3527
2015 Q1	$3K	Hold	3	–	–	﹤0.01%	3949
2014 Q4	$3K	Hold	3	–	–	﹤0.01%	4014
2014 Q3	$3K	Hold	3	–	–	﹤0.01%	3982
2014 Q2	$5K	Sell	3 -50	-94%	-$98.9K	﹤0.01%	3882
2014 Q1	$114K	Hold	53	–	–	﹤0.01%	3287
2013 Q4	$122K	Sell	53 -1	-2%	-$2.29K	﹤0.01%	3265
2013 Q3	$154K	Buy	54 +3	+6%	+$14.9K	﹤0.01%	3215
2013 Q2	$467K	Buy	+51	New	+$393K	﹤0.01%	2884

Other funds holding ONCT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

FHA

First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

KLI

Kelman-Lazarov Inc Memphis, Tennessee $763M AUM 17.15% 1-Year Est. Return

BlackRock Investment Management's ONCT Position: Q2 2016 in Review

BlackRock Investment Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2016, closing a stake of 9 shares — an estimated $6K sold.

BlackRock Investment Management first reported a position in ONCT in Q2 2013 and held it in 12 quarters. The position peaked at $467K in Q2 2013. 34 funds tracked by Wall St. Rank hold ONCT as of Q2 2016.

BlackRock Investment Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
BlackRock Investment Management sold 9 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $6K.
BlackRock Investment Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
BlackRock Investment Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $467K in Q2 2013.
34 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.